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e.2012.07Abstract Ovarian cancer is the most common cause of death among women with gynecologic
malignancies. The standard management is maximal surgical cytoreduction followed by systemic
chemotherapy.
The aim of this retrospective study is to evaluate ovarian cancer cases presented at Alexandria Clin-
ical Oncology Department (ACOD) during the years 2008–2010.
Methods and materials: We reviewed the ﬁles of all patients presented at or referred to ACOD from
January 2008 till December 2010 with the diagnosis of ovarian cancer, ovarian epithelial tumor,
ovarian sex cord tumors, border line ovarian tumor and ovarian germ cell tumors.
Results: The study included 116 patients, representing 1.4% of all cancer cases; the mean age for all
patients was 47.9 ± 13.9 years. Only 13.7% of the patients had positive family history. Stages III
and IV were seen in 79.2% of the cases. Epithelial ovarian cancer (EOC) constituted 75% of the
cases, border line tumors 12.9%, granulosa cell tumor 6%, and germ cell tumors 4.3%. Among
EOC, serous cystadenocarcinoma was seen in 58%. For EOC, surgery was the initial step in
80.4% of the cases. Paclitaxel-carboplatin was the most commonly used regimen as ﬁrst line chemo-al oncology department; EOC,
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354 M.F. Mostafa et al.therapy. Response rate to ﬁrst line chemotherapy reached 87.3% (44.8% complete response). The
mean follow up period was 15 months. The progression free survival for EOC after ﬁrst line chemo-
therapy was 10.8 months.
Conclusion: The age incidence of ovarian cancer in our patients is 10 years younger than that seen
in Western countries. EOC constitutes the majority among all ovarian cancer cases, followed by
border line tumors. Papillary serous cystadenocarcinoma predominates other types of EOC. The
response rate of EOC to ﬁrst line chemotherapy was high but the progression free survival was
lower than that seen in the literature.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Malignant ovarian tumors include epithelial ovarian cancer,
germ cell tumors in addition to other less common tumors of
low malignant potential.1
Epithelial ovarian cancer EOC is by far the commonest
among different malignant ovarian tumors, it is the sixth most
frequent cancer in women and the most common cause of
death arising from a female pelvic malignancy.1 More than
50% of epithelial ovarian cancer cases affect patients older
than 60 years and 5–10% of the cases are familial.2 Approxi-
mately 75% of women with epithelial ovarian cancer are diag-
nosed with stage III or stage IV disease. The 5 year survival
rates for stage three ranges between 28% and 50%, and for
stage four around 13%.3
Surgery is the main line of treatment in most of the cases of
epithelial ovarian cancer (EOC), with adjuvant chemotherapy
recommended for patients with stage I C and up.4–6 In locally
advanced and metastatic EOC either primary surgery or neo-
adjuvant chemotherapy followed by surgery is a reasonable
modality.7
In Egypt, there is no national cancer registry, but one of the
important regional registries is Gharbia Population Based
Cancer Registry (GPBCR), according to its publications over
a three years period (2000–2002), 225 ovarian cancer cases
were registered with an average of 75 cases per year. They rep-
resented 2.2% of all incident cancers and accounting for 4.4%
of all newly diagnosed female cancers.8
The other important regional registry in Egypt is Aswan re-
gional registry, in which over the year 2008, thirty-ﬁve cases of
ovarian cancer were registered, representing 5.6% of all female
cancers cases.9
In Alexandria Clinical Oncology Department, we have an
archive with a ﬁling system for all cancer cases presented at
the department together with a manual registry; a new com-
puter based registry is on its way to be established. Studies eval-
uating the magnitude of the problem of ovarian cancer cases
presented at our department are very few and old, so our idea
was to conduct such a study aiming at evaluating ovarian can-
cer cases referred to and presented at the Alexandria Clinical
Oncology Department (ACOD) in the last three years.
1.1. Aim of the study
Evaluating ovarian cancer cases presented and referred to the
clinical oncology department during the last three years from
January 2008 till December 2010, as regards; percentage
among different cancer cases, age distribution, clinico-patho-
logical aspect, stage at presentation, grade at presentation,primary modality of therapy, response to ﬁrst and second line
chemotherapy, and the progression free survival (PFS).
2. Methods
We reviewed of the ﬁles of all patients who presented at or re-
ferred to Alexandria Clinical Oncology Department during the
years from January 2008 till December 2010 with the diagnosis
of ovarian cancer, ovarian epithelial tumor, ovarian sex cord
tumors, border line ovarian tumor and ovarian germ cell tu-
mors. The content of the ﬁles were emptied in excel sheets
and were referred to the statistician (a member of the team)
for statistics.
3. Statistical methods
Analysis was done on stats direct statistical package. Descrip-
tive statistics were used to describe the study sample in terms
of age, histopathology, stage and grade distribution as well
as symptoms and treatment categories. As regards response
to treatment, frequency distributions were used to elicit pro-
portion of patients in each response category.
4. Results
Table 1: Clinico-pathologic criteria in the studied patients.
4.1. Age
The mean age for the whole group of patients in this study was
47.9 ± 13.9 (range 25–80 years), and the median age was
46 years, The age distribution showed two age peaks, the ﬁrst
age peak lies between 30 and 50 years of age, half of the pa-
tients in the study sample were in this group. The second age
peak, which contained approximately one third of the patients,
was seen in the age group 60–69 years.
Analysis of EOC patients alone showed a median age of
47 year, mean 48.5 ± 12.7 year and that all age groups were
represented within the epithelial tumors category: 1% of epi-
thelial tumors were under 30 years, 48% between 30 and
49 years, 16% were aged 50 and 59 years, 32% between 60
and 69 years and only 3% over 70 years.
4.2. Family history
Negative family history for ovarian, breast and colon cancers
was present in 100 (86.2%), while 16 (13.7%) patient reported
positive family history in ﬁrst degree relatives for one of the
previously mentioned cancers.
Table 1 Clinico-pathologic criteria in the studied patients.
Age Number Percentage
Mean age all patients 47.9 years ± 13.9 –
Mean age EOC 48.5 years ± 12.7 –
Positive Family history 16 13.7
Histopathology
EOC: 87 75
Border line tumors: 15 12.9
Granulosa cell tumors: 7 6
Germ cell tumors: 5 4.3
Krukenberg tumors 2 1.7
Total number of cases
in the study
116 100
Grade of the tumor
(all patients)
GI 11 9.4
GII 37 31.8
GIII 53 45.6
Duration of symptoms
Maximum: 18 months –
Minimum: 2 months –
Mean: 6 ± 2.8 months –
Common symptoms
Abdominal discomfort 109 93.9
Abdominal distention 104 89.6
Menstrual irregularities 63 54.3
Pelvic pain 31 26.7
Constipation 11 9.4
Dyspnea 5 4.3
Intermittent intestinal obstruction 3 2.5
Elevated CA 125 level for EOC 87 100
EOC; epithelial ovarian cancer.
Table 2 Stage information in the studied patients.
Stage EOC (%) Border lie
tumors (%)
Granulosa cell
tumors (%)
Germ cell
tumors (%)
I 6.8 86.6 28.5 40
II 8.2 – –
III 50.6 13.3 28.5 –
IV 34.4 – 42.8 60
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A maximum duration of symptoms prior to presentation of
18 months, and a minimum of 2 months with a mean duration
of 6 ± 2.8 months. Duration of symptoms also strongly corre-
lated with stage at presentation by simple linear regression
(p< 0.001).
4.4. Symptom proﬁle
The most common presenting symptoms were abdominal dis-
comfort (109 patients, 93.9%), abdominal distension (104 pa-
tient 89.6%), menstrual irregularities (63 patient 54.3%),
pelvic pain (31 patient 26.7%), constipation (11 patient
9.4%), dyspnea (5 patient 4.3%) and intermittent attacks of
intestinal obstruction (3 patient 2.5%) .
4.5. Histopathological type
The study included 116 patient with ovarian tumors, EOC con-
stituted 75% (87 cases) of the cases, this was followed by bor-
der line tumors accounting for 12.9% (15 cases), then comes
granulosa cell tumor 6% (7 cases), and lastly germ cell tumors
4.3% (5 cases). Two cases were found to be krukenberg metas-
tasis from colon cancer.
Among EOC serous cystadenocarcinoma constituted the
majority of the cases representing 58% of epithelial ovarian
cancers.4.6. Stage
Table 2: Stage information in the studied patients.
For all patients in the study, typical presentation was late;
stage III was the initial presentation in 48 patients (41.3%)
and stage IV in 44 patients (37.9%). Simple linear regression
showed that stage at presentation was strongly correlated to
age at presentation (p< 0.001) which shows that younger pa-
tients are more likely to present early.
For border line tumors; the majority of the cases were pre-
sented in an early stage (86.6% of the cases were stage I and
II); 5 patients (33.3%) had stage I, 8 patients (53.3%) had
stage II, while only 2 patients (13.3%) had stage III c.
Three out of the 5 patients (60%) with germ cell tumor had
stage IV at presentation while the other two patients (40%)
had stage I.
As regards granulosa cell tumor; three out of the seven pa-
tients had stage IV (42.8%), two out of the seven patients had
stage III (28.5%), while only two patients had stage I (28.5%).
The stage distribution for malignant epithelial tumors was
as follows:
Stage I in 6.8% (50% of them having stage I c), stage II in
8.2% (42% having stage II c), stage III in 50.6% (86% having
stage III c presentation) and stage IV in 34.4% of the cases.
All patients who were clinically staged had stage IV disease
and were referred to us from Elshatby university hospital after
biopsy to receive neoadjuvant chemotherapy, as they were con-
sidered inoperable.
4.7. Grade
For the whole group of patients, grade III dominates in 53 pa-
tients (45.6%), grade II in 37 patients (31.8%) and grade I in
11patients (9.4%), while 15 patient (12.9%) were having bor-
der line tumor.
For epithelial tumors; grade I accounted for 9/87(10.3%) of
the patients, grade II 32/87 (36.7%) of the patients and grade
III 46/87 (52.8%) of the patients.
4.8. CA-125
CA-125 was elevated in all patients with epithelial tumor in this
study, normal in sex cord and germ cell tumors. Elevated inhi-
bin was recorded in two patients with granulosa cell tumors.
4.9. Treatment
4.9.1. Surgery
Table 3: Summary of surgery in the studied patients.
4.9.1.1. For epithelialtumors. Surgerywas performed initially in
70/87 cases (80.4%), of which 59 (84.2%) had total abdominal
Table 3 Summary of surgery in the studied patients.
Surgery as a treatment
modality for the whole
studied patients:
Number of
patients
Percentage
Patients started initial
surgery
94* 81
Patients underwent surgery
after neo-adjuvant
chemotherapy
8 6.8
Total patients received
surgery during treatment.
102/116 87.9
Type of surgery
EOC 70/87 80.4
TAH & BSO 59/70 84.2
Debulking 9/70 12.8
Unilateral oophorectomy 2/70 2.8
No residual or
residual < 2 cm
24/70 34.2
Residual > 2 cm 46/70 65.8
Border line tumors
Unilateral oophorectomy 13/15 86.6
TAH & BSO 1/15 6.6
Debulking 2/15 13
Sex cord tumors
TAH & BSO 3/7 42.8
Unilateral oophorectomy 2/7 28.5
Germ cell tumor
Unilateral oophorectomy 2/5 40
* the number includes the two patients with krukenberg metastasis.
Table 4 Type of chemotherapy regimens used in different
lines of treatment for EOC.
Chemotherapy used for
EOC*
Number of
patients
Percentage
First line
Did not receive adjuvant
chemotherapy
3 3.4
Carboplatin–adriamycin–
cyclophosphamide (CAP)
6 6.8
Carboplatin 21 24.1
Carboplatin–
cyclophosphamide
1 1.1
Paclitaxel–carboplatin 56 64.3
Second line
Gemcitabine- carboplatin 17 47.2
Paclitaxel- carboplatin 15 41.6
Gemcitabine 2 5.5
Oral etoposide 2 5.5
Third line
Paclitaxel- carboplatin 2 14.2
Liposomal doxorubicin 3 21.4
Gemcitabine 1 7.1
Tamoxifen 7 50
Etoposide 1 7.1
* Epithelial ovarian carcinoma.
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BSO), 9 (12.8%) patients had debulking and 2 (2.8%) under-
went unilateral oophorectomy.
Of those who underwent surgery 24 patients had no resid-
ual or residual less than 2 cm (34.2% of those who did surgery)
while the majority of those who underwent surgery had a resid-
ual tumor more than 2 cm (65.8%).
4.9.1.2. For border line tumors. 13 out of 15 patients had uni-
lateral oophorectomy, one patient underwent TAH and BSO
and one patient had debulking and the pathology of the last
2 cases revealed in addition to the border line pathology pos-
itivity of the cytology for malignant cell.
4.9.1.3. For germ cell tumors. 3/5 Patients were treated with pri-
mary chemotherapy and 2/5 had unilateral oophorectomy.
4.9.1.4. For sex cord tumors . 3/7 Patients were treated with
TAH BSO, 2/7 with unilateral oophorectomy and 2/7 with pri-
mary chemotherapy.
So, for the whole study group 94 patients had initial surgery
(TAH BSO, unilateral oophorectomy, debulking) including the
two patients diagnosed as having krukenberg tumor. For those
who started chemotherapy, further 8 patients had surgery after
primary chemotherapy. So that in total 102/116 (87.9%) pa-
tients had some sort of surgery during their treatment.
4.9.2. Chemotherapy
Table 4: Types of chemotherapy regimens used in different
lines in EOC.Table 5: The response rate after different chemotherapy
lines in EOC.
4.9.2.1. Non-epithelial ovarian cancer. Twelve non-epithelial
ovarian tumors were included in our study (in addition to bor-
der line tumors), two did not receive chemotherapy, while the
other ten patients had received chemotherapy; complete re-
sponse was achieved in 50% of the cases, 20% had partial re-
sponse and 30% had stable disease. The median progression
free survival was 15 months.
While germ cell tumors were consistently treated with BEP
(bleomycin–etoposide–cisplatin), sex cord tumors were either
treated with BEP (3/7), carboplatin–paclitaxel (2/7) or no che-
motherapy (2/7).
For border line ovarian tumors 2/15 patients (13.3%) re-
ceived chemotherapy because of the presence of malignant
cells in the pathology specimen, which was in the form of 6 cy-
cles (paclitaxel, carboplatin).
4.9.2.2. Epithelial ovarian cancer. Seventeen patients (19.5%)
with epithelial ovarian cancer received primary chemotherapy.
For epithelial ovarian cancer and as a ﬁrst line
chemotherapy;
 Three patients did not receive any adjuvant chemotherapy
after surgery; all of them were having stage IA, GII epithe-
lial ovarian cancer (3.4%).
 CAP (Cisplatin, Adriamycin, and Cyclophosphamide) was
the initial regimen in 6 patients (6.8%).
 Carboplatin alone was the starting regimen for 21 patients
(24.1%).
 Carboplatin, cyclophosphamide were the starting regimen
for one patient (1.1%).
 Paclitaxel, carboplatin were the initial regimen in 56
patients (64.3%).
Table 5 The response rate after different chemotherapy lines in epithelial ovarian cancer.
CR (%) PR (%) SD (%) PD (%)
Response rate to ﬁrst line chemotherapy 44.8 42.5 6.8 5.7
Response rate to second line chemotherapy 27.7 41.6 22.2 8.3
Response rate to third line chemotherapy – – 50 50
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EOC(Table 5);
 39 Patients 44.8% achieved complete response, and retained
their response after 6 cycles.
 37 Patients 42.5% achieved partial response, of them 7
patients converted to complete response after three more
cycles.
 6 Patients 6.8% had stable disease, both after three and six
cycles.
 5 Patients 5.7% had progressed after receiving three cycles.
For epithelial ovarian cancer, 36 patients (41.3%) received
second line chemotherapy, as follows;
 Gemcitabine, carboplatin in 17 patients (47.2%).
 Paclitaxel, carboplatin in 15 patients (41.6%).
 Gemcitabine in 2 patients (5.5%).
 Oral Etoposide tablets in 2 patients (5.5%).
Response rate for patients after second line chemotherapy
(Table 5);
 10 Patients had complete response (27.7%).
 15 Patients had partial response (41.6%).
 8 Patients stable disease (22.2%).
 3 Patients had progressive disease (8.3%).
As a third line, 14 patients (14.7%) received third line sys-
temic therapy, as follows;
 Paclitaxel, carboplatin in 2 patients (14.2%).
 Liposomal doxorubicin, in 3 patients (21.4%).
 Gemcitabine single agent in one patient (7.1%).
 Tamoxifen in 7 patients (50%).
 Etoposide tablets in one patient (7.1%).
Response rate for third line (Table 5);
 7 Stable disease (50%).
 7 Progressive diseases (50%).4.10. Duration of response
The mean follow up period was 15 months (minimum 3 and
maximum 24 months); the progression free survival (PFS)
after ﬁrst line chemotherapy for epithelial ovarian cancer
was 10.8 months.
5. Discussion
5.1. Age
The study included 116 patients diagnosed as having ovarian
tumors, representing 1.4% of all cancer cases presented atAlexandria Clinical Oncology Department ACOD during the
period from January 2008 till December 2010.
For EOC the median age was 47 year and the mean age was
48.5 ± 12.7 years, an age incidence peak which is about one
and a half decade lower than what is seen in Western
populations.10
In the Gharbia population based cancer registry, ovarian
cancer represented 2.2% of all incident cancers and 4.4% of
all newly diagnosed female cancers. The mean age at diagnosis
was 47.2 years and the median age was 49 years.8
In the year 2007, the middle east cancer consortium
(MECC) evaluated the incidence of ovarian cancer among four
member countries in this consortium namely Egypt, Israel, Cy-
prus, and Jordan and compared it to the US SEER data base,
and noticed that, while in Cypriots, Israeli, and US SEER
data, the highest proportion of patients with ovarian cancer
were in the age group from 50 to 69, in Egyptians, Jordanians,
and Israeli Arabs, the highest age group was below the age of
50 years, which is very close to our results.10
Paes et al., in a retrospective study evaluating clinic-patho-
logic characteristics of ovarian tumors in the state of Espirito
Santo in Brazil found that the mean age of diagnosis of ovar-
ian cancer was 54.6 years.11
Malik, in their study evaluating 286 patients with ovarian
epithelial cancer presented at the national cancer institute in
Pakistan during the period from 1993 to 1998, found that
the mean age of presentation was 49.5 ± 13 years.12
So, the age incidence of our patients is similar to that of
other parts of Egypt (Gharbia), Jordan, Israeli Arab and Paki-
stan, while it is nearly 10 years younger than US seer data, Is-
raeli, Cypriots, a notiﬁcation that needs to be studied more
deeply.
5.2. Family history
In our study positive family history for ovarian, breast and co-
lon cancers was present in 13.7% of the patients. In a recent
study evaluating epithelial ovarian cancer among Pakistani
women, the number of patients with positive family history
for cancer was 18.7%.15 In another older study from Paki-
stan,12 20% of the cases had positive family history of cancer.
The results of our study stand midway between the consistent
higher percentages of positive family history in Pakistani stud-
ies and the lower percentage in western data in which only 5–
10% of epithelial ovarian cancer cases have strong family his-
tories,16 further epidemiologic studies are needed to explain
these results.
5.3. Pathology
In our study, EOC predominates constituting 75% of all ovar-
ian cancer cases. Sarwar et al.,13 in a study evaluating epithelial
ovarian cancer at a cancer hospital in Pakistan, mentioned that
epithelial tumors constituted 83.3% of all ovarian cancer cases
in this hospital. These incidences were close to the (66–70%)
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was written in western literature (90%).13,14 In the Middle East
consortium study10, epithelial ovarian tumors ranged between
77.8% and 93.2% of the cases according to the region (it was
the lowest in Egypt 77.8% followed by Jordan 81%, then Is-
raeli Arabs 84.5%, Cyprus 88.4%, US SEER data 91.8%
and Israel 93.2%).
Among our patients with EOC, 58% were serous carcino-
mas, and 17.2% were mucinous carcinomas. In the Middle
East consortium study,10 serous carcinomas predominate with
percentage ranging between 27.2% and 49.9%, followed by
adenocarcinomas, the proportion of mucinous carcinomas
among Egyptians in this study was 16.1% and among Jordani-
ans was 11.7% whereas in Israeli and Cypriot registries the
percentage was low ranging from 6% to 8.7%.
Paes et al., in their study found that 30% of the epithelial
tumors were serous while 13.7% were mucinous.11
In our study, granulosa cell tumor accounted for 6% of the
cases; this was close to the results of the Middle East consor-
tium study where the percentage of the sex cord–stromal tu-
mors was very low especially in Jews and Israeli Arabs.10
In our study, the percentage of germ cell tumors was 4.3%
of all ovarian cancer cases presented to our department.
According to the Middle East consortium study,10 our results
mimic those of US SEER, Cypriot, and Israeli Jewish but less
than other Arabian countries where the incidence of germ cell
tumors is higher (7.2–12.1%).
So, the incidence of EOC among all ovarian cancer cases in
our study is similar to the incidence in Pakistani and Indian
hospitals, and some Middle East countries, but differs from
US SEER, Israeli data.
5.4. Stage
For all patients in this study, typical presentation was late;
stages III and IV were seen in 79.2% of the cases. Our results
were similar to results presented by Malik,12 where 78% of the
cases were having stages III and IV at presentation. Another
Asian study showed higher stage at presentation in Pakistan
and south Asian countries compared to the Western popula-
tion (stages III & IV 67% in this study).13 Paes et al.,11 found
that stages III and IV accounted for only 56.2% of his cases.
5.5. Tumor markers
In our study CA-125 was elevated in all epithelial tumors,
while in the study done by Sarwar et al.,13 CA-125 was ele-
vated in only 70% of the cases of epithelial ovarian cancer.
5.6. Bi-laterality
Only 13% of all ovarian tumors in this study were having
bilateral disease, a result which is close to the 17.2% incidence
that was seen in an Asian study evaluating ovarian cancer at a
cancer hospital in a developing country,13 and is much less
than 35% in Gharbia population bases cancer registry.8
5.7. Treatment
5.7.1. Surgery
5.7.1.1. For epithelial tumors. 80.4% of our patients were trea-
ted initially with surgery. Singh et al.,14 in the study evaluatingovarian cancer in oriental women from Singapore found that
surgery was the primary treatment modality in 97% of the
cases, while Sehouli et al.,17 in their review to 372 consecutive
patients with advanced ovarian cancer in a university hospital
in Berlin found that 89% of the cases underwent surgery.
Thrall et al.,18 in their report evaluating patients with ad-
vanced ovarian epithelial carcinoma in the Medicare popula-
tion found that surgery was performed initially in 58.8% of
the women.
The slightly lower incidence of our patients’ starting surgery
in comparison to the German and the Singapore trials could be
explained by the fact that there is no established multidisciplin-
ary team between our department and the gynecology depart-
ment evaluating every case and putting plans for further
management.
Of those who underwent surgery 34.2% of our cases had
optimum cytoreduction surgery (no residual or residual less
than 2 cm). Gerestein et al.,19 in the study evaluating surgery
in 115 patients with stages III and IV ovarian cancer in the
south west of the Netherlands found that optimal surgery
was done in only 45% of the cases. Brand et al.,20 in the survey
study among gynecologist performing surgery for ovarian car-
cinoma in Australia and New Zealand found that about 65%
of the surgeons perform optimal cytoreductive surgery.
It is obvious from the comparison that in our series, opti-
mal cytoreductive surgery is performed in a much less fre-
quency than done in Western countries, and this can be
explained by; the very late presentation in most of our cases,
and absence of multidisciplinary team evaluating all the cases
before surgery.
5.7.1.2. For border line tumors. All our patients with border line
tumors underwent surgery, 86.6% of the patients had unilate-
ral oophorectomy (all stage I and II tumors had conservative
surgery), 6.6% underwent TAH and BSO and 6.6% had deb-
ulking surgery. In contrast to our series, only 35% of the cases
in an Italian study done by Lervollno et al.21, (evaluating 20
patients with border line ovarian tumors) had conservative
surgery, while 63% of the cases had TAH & BSO. Darai et
al.22 in the study evaluating 43 cases of ovarian border line tu-
mors found that conservative surgery was done in 51.1%.
The small number of the cases with sex cord and germ cell
tumor in this study will prevent further discussion of the differ-
ent surgical approaches.
5.7.2. Chemotherapy
In our study, only three patients having epithelial ovarian car-
cinoma did not receive any adjuvant or neo-adjuvant chemo-
therapy, all of them were having stage IA and GII (3.4%),
while 19.5% of the cases in our study started neo-adjuvant
chemotherapy.
As regards the type of chemotherapy regimen used, Paclit-
axel-carboplatin was the most frequently used regimen as ﬁrst
line in 64.3% of the cases, followed by carboplatin single agent
in 24.1% of the cases (carboplatin was used alone for fragile
patients with moderate performance status or when there is
shortage in paclitaxel because of the limited resources).
The response rate to the ﬁrst line chemotherapy (including
both neo-adjuvant and following surgery) after three chemo-
therapy cycles was seen in 87.3% of the cases (CR 44.8%), if
we added cases with stable disease after three cycles chemo-
therapy, the overall response will increase to 94.1%, only
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chemotherapy.
Different response rates were seen in the literature, with dif-
ferent percentages of complete responses;
Thigpen et al.,23 in the GOG study protocol 47, found that
the complete response rate for the cisplatin containing arm
reached 51%. The response rate to paclitaxel followed by
either cisplatin or carboplatin in the study done by Neijt, et
al.,24 ranged between (64–74%), while the pathological com-
plete response in the study done by Ozols et al.,25 comparing
paclitaxel plus cisplatin versus paclitaxel plus carboplatin,
was nearly similar among both groups (46 vs. 53%).
McGuire et al.,26 compared cisplatin–paclitaxel vs. cis-
platin–cyclophosphamide in patients with stage IV or sub-
optimally debulked stage III EOC, found that the overall
response was (73% vs. 60%), and the clinical CR (51% vs.
31%).
It is obvious after comparing our results to those of the
large international studies that the response rate including clin-
ical complete response in our patients is closely similar to those
of the international studies.
In our study, for epithelial ovarian cancer, the mean follow
up period was 15 months (a minimum period of 3 months and
a maximum of 24 months) and the progression free survival
(PFS) after ﬁrst line chemotherapy was 10.8 months.
After reviewing the PFS in different international studies, it
ranged between 11 and 21 months which is much higher than
that was seen in our study.23–27
The possible explanation of that difference in progression
free survival between our study and the different international
studies could be explained by; ﬁrst; the number of the patients
in our study was small in comparison to those studies, second;
no standard chemotherapy protocol was given among all pa-
tients in our study, and third; the high frequency of chemother-
apy under-dosage and frequent interruption of the treatment
were due to limited resources and unavailability of the drugs
specially paclitaxel.
Thirty-six patients (41.3%) diagnosed as having epithelial
ovarian cancer received second line chemotherapy.
Gemcitabine-carboplatin was the most frequently used reg-
imen as second line chemotherapy in 47.2% followed by pac-
litaxel–carboplatin in 41.6% of the cases, and then comes
gemcitabine and Etoposide as single agents 5.5% each.
What was very evident in our study was the response rate to
second line chemotherapy which reached nearly 69.3% of them
27.7% achieved second complete responses (the response was
assessed radiologically and by tumor markers).
In the western studies the response rate for platinum sensi-
tive patients ranged roughly from 30% to 60% with a com-
plete response ranging between 10% and 30%. The response
rate in platinum resistant patients is much less.28
The high response rate to platinum containing second line
chemotherapy in our study could be explained by the high inci-
dence of platinum sensitive patients in our study, but also the
small number of the patients in the study may contribute to
these results.
Nearly fourteen percent (14.7%) of the patients diagnosed as
having epithelial ovarian cancer received third line chemotherapy,
tamoxifen, liposomal doxorubicin, gemcitabine, paclitaxel and
etoposide were the most frequently used agents in the third line.
On the contrary to the high response rate in the ﬁrst and
second line chemotherapy, none of our patients had completeor partial response to any of the previously mentioned agents,
only stable disease in 50% of the cases and progressive disease
in the other 50% of the cases.
Tangjitgamol et al.,29 reported the response rate in 51 pa-
tients receiving third line chemotherapy for epithelial ovarian
carcinoma at MD Anderson Cancer Center, and found the re-
sponse rate was modest; the overall response rate was 16%
(eight cases), with 2% complete response (one case) and 14%
partial response (seven cases). Stable disease was achieved in
31% (16 cases).
Forty-four patients received third line chemotherapy with a
response rate of 41% in a retrospective study evaluating 172
patients with ovarian epithelial cancer treated at the national
cancer institute in Japan from the year 1999–2005, this was re-
ported in a study by Nishio et al.30
For sex cord tumors and germ cell tumors, the number of
the cases was too small for comparison or any statistical
conclusions.
6. Conclusions
The age incidence of ovarian cancer in our patients is ten years
younger than what is reported in US SEER data and other
Western countries. EOC constitutes the majority among all
our ovarian cancer cases, followed by border line tumors. Pap-
illary serous cystadenocarcinoma predominates other types of
EOC. For all patients in this study, typical presentation was
late; stages III and IV predominate. The response rate of
EOC to ﬁrst line chemotherapy was high but the progression
free survival was lower than what is reported in the western
literature.
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